MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
32.98
-2.84
-7.93%
After Hours: 32.95 -0.03 -0.09% 16:25 11/13 EST
OPEN
36.39
PREV CLOSE
35.82
HIGH
36.98
LOW
32.23
VOLUME
793.60K
TURNOVER
--
52 WEEK HIGH
47.97
52 WEEK LOW
8.75
MARKET CAP
1.70B
P/E (TTM)
-4.4341
1D
5D
1M
3M
1Y
5Y
1D
Stifel Nicolaus Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
TipRanks · 16h ago
Spyre Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 1d ago
Baird Maintains Outperform on Spyre Therapeutics, Raises Price Target to $65
Benzinga · 1d ago
Spyre Therapeutics price target raised to $65 from $50 at Baird
TipRanks · 1d ago
BTIG Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
TipRanks · 1d ago
Promising Phase 1 Results and Strategic Milestones Support Buy Recommendation for Spyre Therapeutics’ SPY001
TipRanks · 2d ago
Spyre Therapeutics Reports Promising Trial Results for SPY001
TipRanks · 2d ago
SPYRE THERAPEUTICS INC <SYRE.O>: BTIG RAISES TARGET PRICE TO $70 FROM $40
Reuters · 2d ago
More
About SYRE
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.